Ribavirin in acute viral hepatitis

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Acute viral hepatitis, excluding hepatitis B, presents a significant clinical challenge.
• Current treatment options for uncomplicated viral hepatitis aim to manage symptoms and support recovery.
• Understanding the efficacy of antiviral agents like ribavirin is crucial for optimizing patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of ribavirin in treating acute uncomplicated viral hepatitis (non-B).
• To assess the impact of ribavirin on key biochemical markers of liver injury.
• To determine the safety profile of ribavirin in this patient population.

Main Methods:

• A double-blind, placebo-controlled trial involving 30 patients with acute uncomplicated viral hepatitis (non-B).
• Patients received either ribavirin (200 mg orally four times daily for two weeks) or a placebo.
• Clinical and laboratory parameters, including ALT, AST, and bilirubin, were monitored on days 5, 10, and 14.

Main Results:

• Ribavirin-treated patients showed significantly lower mean ALT and AST levels on days 5, 10, and 14 compared to placebo.
• Serum bilirubin levels were significantly reduced in the ribavirin group on days 10 and 14.
• Ribavirin therapy was well-tolerated, with no significant adverse effects reported.

Conclusions:

• Ribavirin therapy accelerates the normalization of biochemical parameters in acute uncomplicated non-B viral hepatitis.
• The study supports ribavirin as an effective treatment for improving liver function markers in these patients.
• Ribavirin demonstrates a favorable safety profile for managing acute viral hepatitis (non-B).